<bill session="114" type="h" number="4669" updated="2017-06-02T21:47:56Z">
  <state datetime="2016-03-02">REFERRED</state>
  <status>
    <introduced datetime="2016-03-02"/>
  </status>
  <introduced datetime="2016-03-02"/>
  <titles>
    <title type="short" as="introduced">Advancing Standards in Regenerative Medicine Act</title>
    <title type="official" as="introduced">To support the establishment of a Standards Coordinating Body in Regenerative Medicine and Advanced Therapies.</title>
    <title type="display">Advancing Standards in Regenerative Medicine Act</title>
  </titles>
  <sponsor id="412257"/>
  <cosponsors>
    <cosponsor id="400352" joined="2016-06-03"/>
  </cosponsors>
  <actions>
    <action datetime="2016-03-02">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-03-02" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2016-03-04">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="114" type="s" number="2443"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Cell biology and embryology"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Genetics"/>
    <term name="Medical research"/>
    <term name="Organ and tissue donation and transplantation"/>
    <term name="Public-private cooperation"/>
  </subjects>
  <amendments/>
  <summary date="2016-03-02T05:00:00Z" status="Introduced in House">Advancing Standards in Regenerative Medicine Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to facilitate the establishment of a public-private Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. The FDA must work with this body to develop standards to support the development and review of regenerative medicine products.</summary>
  <committee-reports/>
</bill>
